S&P Futures
3,845.25 +11.25 (+0.29%) Dow Futures
31,002.00 +66.00 (+0.21%) Nasdaq Futures
11,857.25 +48.75 (+0.41%) Russell 2000 Futures
1,745.20 +3.50 (+0.20%) Crude Oil
101.15 +1.65 (+1.66%) Gold
1,770.50 +6.60 (+0.37%)
9 Meters Biopharma, Inc. (NMTR)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.2249 |
| Open | 0.2299 |
| Bid | 0.2130 x 1200 |
| Ask | 0.2161 x 1200 |
| Day's Range | 0.2100 - 0.2350 |
| 52 Week Range | 0.2100 - 1.4600 |
| Volume | |
| Avg. Volume | 3,184,745 |
| Market Cap | 55.371M |
| Beta (5Y Monthly) | 0.34 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1680 |
| Earnings Date | May 16, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.25 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for NMTR
Related Research
- 9 Meters Biopharma, Inc.Daily – Vickers Top Buyers & Sellers for 09/09/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat10 months agoArgus Research
- American City Business Journals
Chapel Hill company given extension to regain Nasdaq compliance
A medical device company that set up shop in Chapel Hill last year has received some relief in its bid to remain listed on the Nasdaq Capital Market.
- ACCESSWIRE
9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome
Initial Draw of $20 Million to Support Funding Phase 3 Development of Vurolenatide in Short Bowel SyndromeRALEIGH, NC / ACCESSWIRE / June 30, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced it has entered into a senior secured convertible notes facility with a single lender for up to $70 million that is part of an overall financing strategy to support the continued develop
- ACCESSWIRE
9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome
(NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced positive preliminary topline results from the VIBRANT study (VurolenatIde for short Bowel syndrome Regardless of pArenteral support requiremeNT), its Phase 2 trial of vurolenatide, a proprietary, long-acting GLP-1 receptor agonist in development for the treatment of adult patients with short bowel syndrome (SBS). Based on positive results from this Phase 2
